皮下注射CAMPATH-1H治疗氟达拉滨耐药/复发的慢性淋巴细胞白血病和B原淋巴细胞白血病。

Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia.

作者信息

Bowen A L, Zomas A, Emmett E, Matutes E, Dyer M J, Catovsky D

机构信息

Academic Department of Haematology and Cytogenetics, Royal Marsden NHS Trust, London.

出版信息

Br J Haematol. 1997 Mar;96(3):617-9. doi: 10.1046/j.1365-2141.1997.d01-2061.x.

DOI:10.1046/j.1365-2141.1997.d01-2061.x

PMID:9054672

Abstract

Seven patients with B-cell leukaemia - six with chronic lymphocytic leukaemia (CLL) and one with B-prolymphocytic leukaemia (B-PLL) - were treated with CAMPATH-1H*, a genetically reshaped CD52 monoclonal antibody, administered subcutaneously (s.c.) three times a week for 6-12 weeks. Four were resistant to, and three had had a short partial remission (PR) following, fludarabine chemotherapy. The patient with B-PLL achieved complete remission and three patients with CLL attained PR; two of the latter were retreated. The three remaining patients were non-responders. Three patients were transfusion-dependent before CAMPATH and all three became transfusion-independent after treatment. The overall median survival from starting CAMPATH-1H was 11 months. Three patients reactivated cytomegalovirus (CMV) during the course of treatment, and two were treated with, and responded to, ganciclovir.

摘要

7例B细胞白血病患者——6例慢性淋巴细胞白血病（CLL）患者和1例B原淋巴细胞白血病（B-PLL）患者——接受了CAMPATH-1H*治疗，这是一种基因改造的CD52单克隆抗体，每周皮下注射3次，持续6至12周。4例对氟达拉滨化疗耐药，3例在氟达拉滨化疗后有短期部分缓解（PR）。B-PLL患者达到完全缓解，3例CLL患者达到PR；后者中有2例接受了再次治疗。其余3例患者无反应。3例患者在接受CAMPATH治疗前依赖输血，治疗后均不再依赖输血。从开始使用CAMPATH-1H起的总中位生存期为11个月。3例患者在治疗过程中巨细胞病毒（CMV）重新激活，2例接受更昔洛韦治疗并产生反应。